ghk-cu hair growth study topical for Growth: Protocols GHK Cu - is this

First, it upregulates growth hormone receptor expression at the tendon-to-bone junction, making tissue more responsive to endogenous growth signals

While findings are promising, more human studies are needed to better understand its full effects and long-term benefits

The Lancet (2021) This Phase 2 dose-finding trial randomized adults with overweight or obesity without diabetes to cagrilintide at doses from 0.3 to 4.5 mg weekly, placebo, or liraglutide 3.0 mg daily as an active comparator across 57 sites in 10 countries

91 The MAD cohort randomized to 420 mg monthly lost 14.5% of their total body weight after receiving 3 doses of treatment and maintained 10% total weight loss approximately 2.5 months after last dose